Nadian Bio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
6
Nadian Bio General Information
Description
Developer of cancer drugs intended to provide neutropenia medications. The company develops anti-cancer combination therapy, cancer treatment side effects, and aging disease treatment, enabling patients to lower the side effects of drugs and enhance the therapeutic effect of existing drugs.
Contact Information
Website
www.nadianbio.comCorporate Office
- Wonkwang University Incubation Center, 460 Iksan-daero
- Room 201-1, 4105, 4th Floor, Startup Support Center
- Iksan, Jeollabuk 54538
- South Korea
Corporate Office
- Wonkwang University Incubation Center, 460 Iksan-daero
- Room 201-1, 4105, 4th Floor, Startup Support Center
- Iksan, Jeollabuk 54538
- South Korea
Nadian Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 4. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 3. Later Stage VC (Series C) | 01-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 20-Aug-2019 | $10M | $13.4M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 06-Apr-2018 | $3.38M | $3.38M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nadian Bio Patents
Nadian Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024147659-A1 | Composition and soft capsule formulation comprising naphthoquinone-based compound | Inactive | 05-Jan-2023 | ||
| JP-2023533187-A | A pharmaceutical composition for preventing or treating cancer comprising a naphthoquinone-based compound and an immune checkpoint inhibitor as active ingredients | Active | 10-Jul-2020 | ||
| JP-7573657-B2 | A pharmaceutical composition for preventing or treating cancer comprising a naphthoquinone-based compound and an immune checkpoint inhibitor as active ingredients | Active | 10-Jul-2020 | ||
| AU-2021305584-A1 | Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients | Pending | 10-Jul-2020 | ||
| AU-2021305584-A8 | Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients | Pending | 10-Jul-2020 | A61P35/00 |
Nadian Bio Signals
Nadian Bio Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cloud IB | Venture Capital | Minority | ||
| DS Asset Management | Asset Manager | Minority | ||
| Jeonbuk Technology Holdings | Venture Capital | Minority | ||
| Korea Development Bank | VC-Backed Company | Minority | ||
| SJ Investment Partners | Venture Capital | Minority |
Nadian Bio FAQs
-
When was Nadian Bio founded?
Nadian Bio was founded in 2016.
-
Where is Nadian Bio headquartered?
Nadian Bio is headquartered in Iksan, South Korea.
-
What is the size of Nadian Bio?
Nadian Bio has 3 total employees.
-
What industry is Nadian Bio in?
Nadian Bio’s primary industry is Drug Discovery.
-
Is Nadian Bio a private or public company?
Nadian Bio is a Private company.
-
What is Nadian Bio’s current revenue?
The current revenue for Nadian Bio is .
-
How much funding has Nadian Bio raised over time?
Nadian Bio has raised $22M.
-
Who are Nadian Bio’s investors?
Cloud IB, DS Asset Management, Jeonbuk Technology Holdings, Korea Development Bank, and SJ Investment Partners are 5 of 6 investors who have invested in Nadian Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process